Ergometrine functions by directly stimulating the uterine muscle, thereby increasing both the force and frequency of contractions. This mechanism of action facilitates uterine contractions, diminishes postpartum bleeding, and serves as a preventive measure against premature birth. Additionally, ergometrine instigates contractions of the cervix. The intensified uterine contractions aid in hemostasis by contracting the uterine wall around bleeding vessels at the placental site. Notably, the drug’s oxytocic effect becomes particularly sensitive toward the end of pregnancy, rendering it effective in various obstetric scenarios. Moreover, ergometrine induces arterial vasoconstriction by stimulating alpha-adrenergic and serotonin receptors, contributing to the reduction of bleeding.
Ergometrine’s spectrum involves promoting uterine contractions, preventing postpartum bleeding, and reducing excessive bleeding after delivery. It is also employed to improve uterine tone and elasticity in the postpartum period, playing a crucial role in addressing conditions related to uterine contraction and bleeding in obstetric and gynecological contexts.